Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
This invention relates generally to a method of preparation of a phyto-percolate having enzymatic, specifically fibrinolytic, activity in the body of mammals, including humans. The phyto-percolate is derived from fresh water mixture including algae that produces an enzyme having proteolytic activity. The invention further relates to the use off the phyto-percolate in a variety of disease states.
1 . A method of treating or preventing a disease or disorder in a human that is capable of being treated or prevented by phyto-percolate, said method comprising administering to human in need of such treatment or prevention a therapeutically effective amount of phyto-percolate.
2 . The method according to claim 1 wherein said disease is diabetes and said therapeutically effective amount is about 1 ounce to about 12 ounces in divided daily doses of 1-2 oz. of said phyto-percolate.
3 . The method according to claim 1 wherein said disease is HIV and said therapeutically effective amount is about 1 ounce to about 12 ounces in divided daily doses of 1-2 oz. of said phyto-percolate.
4 . The method according to claim 1 wherein said disease is cystic acne and said therapeutically effective amount is about 1 ounce to about 12 ounces in divided daily doses of 1-2 oz. of said phyto-percolate.
5 . The method according to claim 1 wherein said disease is high blood pressure and said therapeutically effective amount is about 1 ounce to about 12 ounces in divided daily doses of 1-2 oz. of said phyto-percolate.
6 . The method according to claim 1 wherein said disease is cancer and said therapeutically effective amount is about 1 ounce per hour of said phyto-percolate during chemotherapy treatment.
7 . The method of claim 1 wherein said disease or disorder is selected from the group consisting of cancer, diabetes, arthritis, cardio-vascular disease, cerebral vascular disease peripheral vascular disease, compromised immune system disorders, HIV/AIDS, and metabolic disorders.
8 . The method of claim 1 wherein said disease or disorder is a compromised immune system caused by chemotherapy.
9 . The method of claim 7 wherein said compromised immune system and compromised liver function are caused by the HIV virus or by anti-viral therapies.
10 . The method of claim 9 wherein said therapeutically effective amount of phyto-percolate is administered in conjugation with protease inhibitors, specifically protease inhibitors that block the replication of HIV.
11 . The method of claim 9 wherein said therapeutically effective dosage is from about 1 ounce to about 12 ounces per day.
12 . The method of claim 11 wherein said therapeutically effective dosage is from about 2 ounces to 4 ounces a day.
13 . A method of producing a phyto-percolate comprising the steps of:
(i) providing a fresh water algal and bacterial culture of ATCC Deposit #: PTA-5863
(ii) growing said algal and bacterial culture in purified water;
(iii) feeding said culture a nutrient blend to produce phyto-percolate;
(iv) decanting said phyto-percolate from said culture; and
(v) filtering said decanted phyto-percolate.
14 . The method according to claim 13 , wherein said filtering step is by size exclusion.
15 . The method according to claim 13 , wherein said filtering step preserves enzymatic activity of said phyto-percolate.
16 . The method according to claim 13 , wherein said fresh water algal and bacterial culture contains at least four said green algae, one said moss species and nine said listed bacterial species.
17 . The method according to claim 13 , wherein said nutrient blend is a liquid extract of live Saccharomyces cerevisiae.
18 . The method according to claim 17 , wherein said live Saccharomyces cerevisiae is introduced into said cultures as a means of stimulating enzymatic production by said algal and bacterial culture.